Expanding health insurance to the poor has become one of the most popular development interventions of the past two decades. Governments from Ghana to Indonesia have launched ambitious subsidy schemes, and donors have invested billions on the premise that removing the price barrier to care will save lives.

The logic seems airtight. Poor households face catastrophic health expenditures that push them deeper into poverty. Subsidize insurance, and they gain access to services they previously couldn't afford. Coverage expands, utilization rises, health improves.

Yet a growing body of rigorous evidence tells a more sobering story. Enrollment often surges when subsidies arrive, but the downstream effects on health service use and actual health outcomes are frequently modest, uneven, or absent altogether. Understanding why requires looking past the enrollment statistics and examining what happens when a newly insured patient walks into a clinic that isn't prepared to help them.

Subsidized insurance programs have proven remarkably effective at their most immediate objective: enrolling people. Ghana's National Health Insurance Scheme reached roughly 40 percent of the population within a decade of launch. Indonesia's Jamkesmas program covered over 76 million poor citizens at its peak. Colombia's subsidized regime enrolled more than 22 million low-income residents.

Randomized evaluations reinforce this pattern. When researchers offered heavily subsidized or free insurance to poor households in Nicaragua, Vietnam, and rural China, take-up rates climbed substantially compared to control groups. Price elasticity of demand for insurance among poor households is high, and subsidies work as designed on this dimension.

These enrollment gains are not trivial. Insurance coverage provides financial protection against catastrophic health spending, and multiple studies document reductions in out-of-pocket expenditures among enrolled households. For a family one illness away from selling productive assets, this protection matters even when other outcomes remain unchanged.

The problem arises when policymakers and evaluators treat enrollment as a proxy for the deeper goals of insurance: improved access to care and better health. Coverage is a necessary but insufficient step, and conflating the two has led to premature declarations of success in program after program.

Takeaway

Enrollment measures policy uptake, not policy success. A program can achieve impressive coverage numbers while delivering little of what coverage was meant to enable.

The evidence on whether newly insured populations actually use more health services is mixed and often disappointing. A landmark evaluation of Mexico's Seguro Popular found significant enrollment gains but limited effects on utilization of covered services and no detectable improvement in mortality or morbidity outcomes over the study period.

Similar patterns appear elsewhere. Studies of Ghana's NHIS show modest increases in outpatient visits but weaker effects on maternal health indicators and child mortality. Evaluations of India's RSBY program documented enrollment success but found limited impact on out-of-pocket spending for inpatient care and inconclusive effects on health status.

Several mechanisms explain this gap. Poor households face non-price barriers that insurance cannot address: distance to facilities, transportation costs, opportunity costs of time, low health literacy, and mistrust of the formal medical system. Reducing the price of care to zero does little when the shadow price of accessing that care remains prohibitive.

There is also the question of what services insurance actually covers. Many subsidized schemes reimburse hospitals for inpatient care while leaving primary and preventive services underfunded, incentivizing costly late-stage interventions rather than the routine care that drives population health outcomes.

Takeaway

Price is only one barrier to healthcare. When distance, time, trust, and knowledge remain unaddressed, removing the price tag can produce coverage without care.

Even when insured patients arrive at facilities, the quality of care they receive often determines whether coverage translates into health. And here, the evidence is unforgiving. Provider absenteeism in public clinics across South Asia and Sub-Saharan Africa routinely exceeds 30 percent. Diagnostic accuracy in standardized patient studies is frequently below 50 percent, even for common conditions.

Insurance programs typically operate on the assumption that adequate supply exists and merely needs to be financed. In practice, expanding demand through subsidies in a system with fixed or degraded supply produces predictable results: longer queues, shorter consultations, stockouts of essential medicines, and providers rationing care through informal fees that reintroduce the very financial barriers insurance was meant to remove.

The Karnataka RSBY evaluation found that a substantial share of insurance claims went to hospitals with limited capacity to deliver quality care, raising concerns that subsidy funds were flowing without corresponding health benefits. In some settings, provider payment mechanisms actively distort care, rewarding volume over quality and elective procedures over essential services.

This is the fundamental design flaw in demand-side financing when supply-side conditions are weak. Insurance is a financing mechanism, not a health system. Pouring money through a broken pipe does not deliver water.

Takeaway

You cannot buy your way into care that does not exist. Financing reforms without corresponding investments in service delivery capacity treat the symptom while ignoring the constraint.

The evidence does not condemn health insurance subsidies. It complicates them. Coverage expansion offers real financial protection and is often politically achievable when broader health system reform is not. These are genuine gains worth preserving.

But if the goal is improved health among the poor, insurance alone will rarely deliver. The binding constraints are usually elsewhere: in absent providers, empty pharmacies, distant facilities, and diagnostic failures that no reimbursement scheme can fix.

Effective policy design begins with honest diagnosis of where the system actually breaks down. Subsidies belong in the toolkit, but they work best when paired with investments in the boring, unglamorous supply-side reforms that determine whether a covered patient becomes a healthier one.